Modulate Bio

The Harvard Innovation Labs supports over 6,000 ventures across multiple industries, including more than 1,000 ventures in the current academic year. Founders backed by the Labs have collectively raised over $8 billion in funding and created solutions impacting millions. The program continues to foster high-impact startups through mentorship and resources.

Jun 2025Harvard Innovation LabsNews article

Harvard’s 2025 President’s Innovation Challenge awards ventures tackling major challenges. One project develops medical solutions to safeguard mothers during childbirth. Another explores cost-effective hydrogen transport methods. A third applies AI and robotics to modernize traditional hair braiding techniques.

May 2025Harvard GazetteNews article

Novaterra invests in **Modulate Bio**, a biotech company developing advanced therapies for central nervous system (CNS) disorders, including epilepsy and Essential Tremor (ET). The company targets unmet medical needs in neurological treatments, backed by Novaterra alongside Pillar VC. Modulate Bio focuses on innovative solutions to address critical challenges in CNS disorder management.

Oct 2024MediumNews article

Harvard’s 2024 President’s Innovation Challenge finalists include projects like **AI-driven plant disease diagnostics**, **medical devices for trauma surgeons**, and **financial technology for African small businesses**. These initiatives address critical gaps in healthcare, agriculture, and financial inclusion through applied innovation. The challenge highlights cross-disciplinary approaches to global challenges.

Mar 2024Harvard GazetteNews article